Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
338.36
+0.87 (+0.26%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
61
62
Next >
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
↗
March 20, 2025
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Via
Benzinga
Behind the Scenes of Amgen's Latest Options Trends
↗
March 20, 2025
Via
Benzinga
Prediction: These 2 Stocks Will Outperform the Market Through 2030
↗
March 18, 2025
Via
The Motley Fool
Motley Fool Market Cap Showdown: Bill Barker vs. Emily Flippen
↗
March 14, 2025
Via
The Motley Fool
Amgen's Options: A Look at What the Big Money is Thinking
↗
March 12, 2025
Via
Benzinga
Assessing Amgen: Insights From 9 Financial Analysts
↗
March 05, 2025
Via
Benzinga
Behind the Scenes of Amgen's Latest Options Trends
↗
March 04, 2025
Via
Benzinga
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
↗
March 13, 2025
Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with two doses a year.
Via
Benzinga
Is Eli Lilly Stock a Buy?
↗
March 11, 2025
Via
The Motley Fool
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
↗
March 10, 2025
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.
Via
Benzinga
3 Magnificent Growth Stocks to Buy in March
↗
March 08, 2025
Via
The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
↗
March 07, 2025
Via
The Motley Fool
Looking Into Amgen's Recent Short Interest
↗
February 19, 2025
Via
Benzinga
Amgen Unusual Options Activity For February 12
↗
February 12, 2025
Via
Benzinga
2 Reasons to Watch AMGN and 1 to Stay Cautious
March 06, 2025
Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.
Via
StockStory
Topics
Stocks
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
↗
March 06, 2025
Via
Benzinga
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 05, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
↗
March 03, 2025
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Via
Benzinga
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform
↗
February 28, 2025
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.
Via
Benzinga
Topics
ETFs
Stocks
This Could Be the Best GLP-1 Stock to Buy in 2025
↗
February 28, 2025
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
February 26, 2025
Via
Benzinga
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
↗
February 25, 2025
Via
The Motley Fool
Topics
Stocks
Synchronicity: Denying The Unexplainable
↗
February 24, 2025
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?
Via
Talk Markets
Topics
Stocks / Equities
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
↗
February 20, 2025
Tariffs could have big impact on earnings in 2025.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 11, 2025
Via
Benzinga
Gilead Sciences (GILD) Q4 Earnings: What To Expect
February 10, 2025
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect.
Via
StockStory
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
↗
February 10, 2025
Via
The Motley Fool
3 Fabulous Dividend Stocks to Buy in February
↗
February 09, 2025
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
February 09, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Via
StockStory
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
↗
February 07, 2025
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...
Via
Stocktwits
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
61
62
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
